GuruTrack
ARWR

ARWR

ARROWHEAD PHARMACEUTICALS IN

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary
ARROWHEAD PHARMACEUTICALS IN (ARWR) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$228.04M; the largest are Baker Bros. Advisors, Renaissance Technologies, Izzy Englander. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 2 trimmed, 2 closed. 2 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders44 also report options
Congress trades2
Price$66.25vs quarter-end-18.72%
Sectors0
This quarter's moves
New1
Added0
Trimmed / sold4
Top holderBaker Bros. Advisors

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Value $162.43M0.8% of portfolio1,992,7832026 Q2

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Value $21.76M— of portfolio266,9002026 Q2
Value $6.37M— of portfolio78,2002026 Q2
Value $4.82M— of portfolio59,1002026 Q2
Value $2.00M— of portfolio24,5002026 Q2
Value $1.26M— of portfolio15,4002026 Q2
Value $1.22M— of portfolio15,0002026 Q2

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.